Lyme disease testing via private, non-PHO laboratories (IGeneX, Armin Labs, and similar)

ND-recommended test reviewed: Lyme disease testing via private laboratory (IGeneX, Armin Labs, LTT-Lyme, CD57, or similar).
Indications reviewed: no validated clinical use identified for these specific assays or interpretive criteria.
Not ordered. Rationale discussed: public health authorities have specifically cautioned that these tests and interpretive methods are not adequately validated. Ref: CDC MMWR 2005; CDC 2026.
Patient informed test available privately via ND. Patient given info page: https://labs.ajaxharwoodclinic.com/lyme-private-lab-tests/patient
Revisit if: a genuine exposure history and compatible clinical picture support pursuing standard two-tier Lyme serology instead.

Indicated when

None recorded.

Not indicated when

• —Ordering or interpreting IGeneX, Armin Labs, or similar private-laboratory Lyme immunoblots using in-house criteria that differ from validated two-tier interpretive criteria [1]
• —Ordering a lymphocyte transformation test (LTT-Lyme) or a CD57 natural killer cell panel to diagnose or monitor 'chronic Lyme disease' [1]
• —Using any of these tests to support a diagnosis of 'chronic Lyme disease' as an explanation for persistent fatigue or multisystem symptoms without a validated positive standard two-tier result and a compatible exposure history

Why not

US public health and regulatory bodies have specifically cautioned that some commercial laboratories run Lyme-related assays 'whose accuracy and clinical usefulness have not been adequately established,' naming lymphocyte transformation tests and non-validated immunoblot interpretive criteria, and noting these tests were also being used to evaluate patients in Canada based on reports from Canada's own National Microbiology Laboratory and the BC Centre for Disease Control [1]. Current CDC guidance continues to recommend only FDA-cleared antibody tests [2]. A positive result from an unvalidated test or interpretive scheme can support a 'chronic Lyme disease' diagnosis and lead to prolonged antimicrobial treatment for a presumed infection that validated testing does not confirm, which carries its own harms without demonstrated benefit.

Better first step

If there is a genuine exposure history and a clinical picture compatible with Lyme disease, use the validated two-tier serology pathway via Public Health Ontario (see the Lyme disease serology (two-tier, via Public Health Ontario) record) rather than a private send-out lab. If Lyme serology, including via PHO, is negative and symptoms persist, investigate the persistent symptoms on their own merits rather than reaching for an unvalidated alternative test to keep the Lyme hypothesis open.

Typical ND rationale

An ND may order or recommend one of these private-lab tests in a patient with persistent symptoms, sometimes after a standard Lyme test came back negative, reasoning that standard testing misses many true Lyme infections and that these specialized labs use more sensitive methods capable of detecting what standard testing cannot.

Ontario coverage & CONO orderability

OHIP status

not_offered_ontario

These tests are not part of the OHIP-insured community Schedule of Benefits for Laboratory Services [4], are not on the CONO list, and are not offered by Public Health Ontario. They are ordered as private, self-pay send-outs to out-of-province or out-of-country laboratories (e.g. IGeneX in the US, Armin Labs in Germany) regardless of who orders them; ND-ordered testing is patient-paid in any case [5]. This session located no Ontario government source addressing these specific tests directly beyond their absence from the Schedule and the CONO list.

CONO orderable

No

Not on the CONO list under any name searched. These are private send-out tests to non-Ontario, non-PHO laboratories, ordered and paid for privately regardless of who orders them.

Linked conditions

• Lyme disease ↗
• "Chronic Lyme disease" ↗
• tired ↗

Counselling script

“If there's a real reason to think you've been exposed to Lyme disease, the right next step is the validated public health testing pathway, not one of these private lab tests. Without that, I wouldn't recommend IGeneX, Armin Labs, LTT-Lyme, or CD57 testing, because health authorities have specifically flagged these as using methods and interpretation criteria that haven't been properly validated. If a validated test result changes or new symptoms fitting Lyme disease develop, we can revisit this.”

Revisit if

• —A genuine tick exposure history and compatible clinical picture develop: pursue standard two-tier serology (see Lyme disease serology (two-tier, via Public Health Ontario)) rather than these tests

References

1. [1]US Centers for Disease Control and Prevention (MMWR) (2005). Notice to Readers: Caution Regarding Testing for Lyme Disease. linkolder guidelineCDC/FDA caution: some commercial labs use assays and Western blot interpretive criteria not adequately validated, including lymphocyte transformation tests and non-validated immunoblot reading; similar unvalidated criteria reported in use in Canada
2. [2]US Centers for Disease Control and Prevention (2026). Testing and Diagnosis for Lyme disease. linkCDC recommends only FDA-cleared antibody tests for laboratory diagnosis of Lyme disease
3. [3]Canadian Rheumatology Association (Pediatric Rheumatology) / Choosing Wisely Canada (2025). Recommendations: Pediatric Rheumatology. linkCRA: do not order Lyme serology without exposure history/endemic residence and a compatible clinical presentation
4. [4]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkCommunity lab tests are insured only when ordered under the Schedule by an authorized prescriber; these tests are not in the Schedule
5. [5]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services